Innaxon, s.r.o. is an early stage development company based at InnoCrystal, Czech Republic.

Innaxon's in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin® and Novo-Pyrexal®) and in-licensed small molecule inhibitors (IAXOTM compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively.

SCHOOL BAGPACK low poly gray
Innaxon sro_3

Innaxon continuously seeks further partnerships with academic, pharmaceutical and clinical research centres to harness innate immunity for therapeutic benefit in the field of

  • vaccine adjuvants
  • immuno(chemo)therapy
  • anti-inflammatory agents